Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: January 7, 2026
Justicia Gendarussa Extract

Gendarussa, Gendarusin A

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): Indopharma, FHI 360, Airlangga University
Active
Last updated: January 7, 2026
Injectable Bioresorbable Subcutaneous Contraceptive

mdc-WWM

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): MedinCell
Active
Last updated: January 7, 2026
Inh-172 Vaginal Non-Hormonal Contraceptive

Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Oregon Health & Science University
Active
Last updated: January 7, 2026
Hormone-Loaded Electrospun Mesh
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Lagos
Active
Last updated: January 7, 2026
GELdom Condom
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Barrier
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Eudaemon, University of Wollongong, Australia
Active
Last updated: January 7, 2026
Fiona LNG IUS
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Phase IV
  • Developer(s)/Researcher(s): Meril Life Science Private Ltd
Active
Last updated: January 7, 2026
Eucontra

68mg Resorbable Implant

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Hera Health Solutions
Active
Last updated: January 7, 2026
ENG Pellets

Casea S

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): GeSea Biosciences, FHI 360, Daré Biosciences, Theramex
Active
Last updated: January 7, 2026
EFdA-p + Progestin Intravaginal Film
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Magee-Women's Research Institute, University of Pittsburgh